A preclinical study by Cho et al. showed that intravenous or subcutaneous administration of human ASC-derived exosomes significantly reduced AD-like symptoms and lowered the expression of Th2 cytokines, including interleukin (IL)-4 and IL-31 in an AD murine model [28]. This evidence concerns the gene IL31 and Alzheimer disease.